GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of Ozempic (semaglutide) and Wegovy (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx,

(CNN) - Patients in the United States can now get the popular diabetes and weight loss drug Ozempic for half the price. Novo Nordisk, the maker of the GLP-1 drug Ozempic, announced Monday that U.S. patients can now get a month’s supply for just under $500. It typically carries a list price of around $1,000 a month.

Price hikes are 'kick in the teeth' for patients who will either have to swallow 170 per cent price increase, or switch to 'almost as good' competitor

The maker of Ozempic is cutting the price of the drug nearly in half for some patients. Novo Nordisk had already cut the price of Wegovy, a medication with the same active ingredient that's approved for weight loss.

At a list price of about $1,080 per month, Lilly's drugs also undercut Novo's official pricing. Ozempic accidentally became a cultural phenomenon. The drug, first delivered to diabetes patients in 2017, had a huge impact on appetite suppression and weight ...

Ozempic price slashed following Donald Trump's demands - will it impact the UK cost? - Novo Nordisk said it has no plans to rise UK prices, despite pressure from Trump